Vaccinex, Inc. (VCNX)
OTCMKTS · Delayed Price · Currency is USD
1.000
0.00 (0.00%)
May 26, 2026, 1:19 PM EST
Vaccinex Revenue
In the year 2024, Vaccinex had annual revenue of $601.00K with 5.44% growth. Vaccinex had revenue of $213.00K in the quarter ending December 31, 2024.
Revenue
601.00K
Revenue Growth
+5.44%
P/S Ratio
4.68
Revenue / Employee
24.04K
Employees
27
Market Cap
2.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 601.00K | 31.00K | 5.44% |
| Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
| Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
| Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
| Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LakeShore Biopharma | 84.75M |
| Adaptimmune Therapeutics | 65.09M |
| CASI Pharmaceuticals | 20.71M |
| Iterum Therapeutics | 390.00K |
| Eastgate Biotech | 137.64K |
| AXIM Biotechnologies | 92.90K |
| Enzolytics | 46.59K |
Vaccinex News
- 27 days ago - Vaccinex Reports 2025 Annual Financial Results - GlobeNewsWire
- 5 months ago - Vaccinex announces $60M revenue sharing agreement with PDV - TheFly
- 1 year ago - Vaccinex to reports new clinical results on pepinemab at ASCO meeting - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 1 year ago - Vaccinex to delist common stock from Nasdaq - TheFly
- 1 year ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire